---
title: An Extension Trial for Patients With Open-Angle Glaucoma Who Participated in the DF6-CL-20-01 Protocol.
nct_id: NCT06230393
overall_status: TERMINATED
sponsor: New World Medical, Inc.
study_type: OBSERVATIONAL
primary_condition: Open Angle Glaucoma
countries: Costa Rica
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT06230393.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT06230393"
ct_last_update_post_date: 2026-03-30
last_seen_at: "2026-05-12T06:38:48.485Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# An Extension Trial for Patients With Open-Angle Glaucoma Who Participated in the DF6-CL-20-01 Protocol.

**Official Title:** An Extension Trial to Evaluate the Long Term Safety and Effectiveness of the STREAMLINE® SURGICAL SYSTEM in Patients With Open-Angle Glaucoma Who Participated in the DF6-CL-20-01 Protocol.

**NCT ID:** [NCT06230393](https://clinicaltrials.gov/study/NCT06230393)

## Key Facts

- **Status:** TERMINATED
- **Why Stopped:** Sponsor decision to close this extension study due to reduction in sample size.
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 17
- **Lead Sponsor:** New World Medical, Inc.
- **Conditions:** Open Angle Glaucoma, Intraocular Pressure
- **Start Date:** 2024-06-01
- **Completion Date:** 2025-12-04
- **CT.gov Last Update:** 2026-03-30

## Brief Summary

The purpose of this study is to evaluate long term safety and effectiveness of the STREAMLINE® SURGICAL SYSTEM

## Detailed Description

A Retrospective, nonrandomized, open-label study to evaluate the long term safety and IOP-lowering effectiveness of STREAMLINE® SURGICAL SYSTEM in patients with open-angle glaucoma who participated in the DF6-CL-20-01 protocol.

## Eligibility

- **Sex:** ALL

```
Inclusion Criteria:

participated in the DF6-CL-20-01 trial.

Exclusion Criteria:

lost to follow up in the DF6-CL-20-01 trial
```

## Interventions

- **STREAMLINE® SURGICAL SYSTEM** (DEVICE) — STREAMLINE® SURGICAL SYSTEM

## Primary Outcomes

- **Change in IOP** _(time frame: 24months; 36 months; 48months, 60 months)_ — From Screening to annual endpoints

## Secondary Outcomes

- **Number of IOP lowering medications** _(time frame: 24months; 36 months; 48months, 60 months)_

## Locations (1)

- Clinica 20/20, San José, Costa Rica

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.whyStopped` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.clinica 20/20|san josé||costa rica` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT06230393.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT06230393*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*